Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Cancer Clinical Trial

Official title:

A Phase 1/2 Multi-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04640246
• Other study ID #: TBX-3400-003
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 25, 2021
• Est. completion date: April 2023

Study information

• Verified date: February 2022
• Source: Taiga Biotechnologies, Inc.
• Contact: Yosef Refaeli
• Phone: +1-720-859-3547
• Email: refaeli[@]taigabiotech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study of treatment with TBX-3400 in subjects with solid malignant tumors that are resistant or refractory to standard therapies.

The subject's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity.

The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response to the tumor.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: April 2023
• Est. primary completion date: January 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for participation in the study:

1. Histologically or cytologically confirmed diagnosis of malignant solid tumor/s

2. Male or female subjects age 18 or older

3. Metastatic tumor that has failed at least one line of therapy with further options being non-curative; or with metastatic tumor and patient declines standard of care therapies and alternatives offered, at the discretion of the investigator

4. At least 28 days or 5 half-lives, since the last dose of medication to treat their malignancy.

5. Measurable or evaluable disease by RECIST version 1.1

6. Capable of understanding and complying with protocol requirements

7. A life expectancy of greater than 12 weeks at Screening

8. ECOG Performance Status of 0 to 2

9. Written informed consent from the patient or the patient's legally acceptable representative prior to the initiation of any study procedures

10. Adequate bone marrow, liver, and renal function at screening as defined below:

• hemoglobin =8.0 g/dL (transfusions allowed)

• total lymphocyte count =500/µL

• absolute neutrophil count =1500/µL

• platelet count =100,000/µL (transfusions allowed)

• alanine transaminase and aspartate transaminase =3.0 times the upper limit of normal (ULN), or =5 times ULN for subjects with known hepatic metastases

• total serum bilirubin =1.5 x the ULN; =2.0 x the ULN if liver metastases are present; subjects with a known history of Gilbert's syndrome (=3.0 x the ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation

• estimated glomerular filtration rate =50 mL/min/1.73 m2 (using Cockcroft Gault formula)

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible for participation in the study:

1. Pregnant or breast feeding

2. Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted

3. Active, symptomatic central nervous system (CNS) metastases. Subjects with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy and the patient is off corticosteroids and is neurologically stable for at least 7 days prior to screening and the Medical Monitor approves subject inclusion

4. Any concurrent uncontrolled illness, including mental illness or substance abuse, which in the opinion of the investigator would make the patient unable to cooperate or participate in the trial

5. Severe uncontrolled cardiac disease within 3 months of study entry, including unstable or new onset angina, myocardial infarction or cerebrovascular accident

6. Women of child-bearing potential who are unable or unwilling to use an acceptable method of contraception

7. Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (in USA: Known infection with human immunodeficiency virus [HIV], hepatitis B or hepatitis C that is not controlled and has any related symptoms)

8. Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher

9. Systemic lupus erythematous (SLE), inflammatory bowel disease, primary Sjogren's syndrome, rheumatoid arthritis, systemic sclerosis, and granulomatosis with polyangiitis; and any other autoimmune condition that, in the opinion of the investigator, may increase the risk of trial participation or trial drug administration, unless reviewed and approved by the medical monitor.

10. Any hematopoietic malignancy

11. Have more than one primary cancer diagnosis within the last 3 years

12. Organ transplant or requiring immune suppression

13. Bullous pemphigoid and other autoimmune diseases of the dermal-epidermal junction; these include bullous pemphigoid, bullous SLE, liner IgA disease, epidermolysis bullosa acquisita, and other pemphigoid variants.

Related Conditions & MeSH terms

• Cancer
• Neoplasms
• Refractory Cancer
• Tumor, Solid

Intervention

Biological:
• TBX-3400
Autologous transfusion

Locations

Country	Name	City	State
Israel	Rabin Medical Center	Petach Tikva
United States	The Angeles Clinic and Research Institute	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Taiga Biotechnologies, Inc.

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Quantification of the concentration of interleukin-1 (IL-1) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	8 months
Other	Quantification of the concentration of interleukin-6 (IL-6) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	8 months
Other	Quantification of the concentration of interferon-alpha (IFN-a) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	8 months
Other	Quantification of the concentration of interferon-gamma inducible protein 10kD (IP-10) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	8 months
Other	Quantification of the concentration of interferon-gamma (IFN-?) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	8 months
Other	Quantification of the concentration of transforming growth factor-beta (TGF-ß) in plasma	Preliminary efficacy assessment to measure activity of TBX-3400	8 months
Primary	The primary endpoint is the incidence and severity of treatment-emergent adverse events (TEAEs), including the incidence of dose-limiting toxicities (DLTs), graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.	Adverse events from subject reporting	8 months
Secondary	Tumor Responses as defined by RECIST	Tumor measurements to assess disease state	8 months
Secondary	Assessment of concentrations of certain proteins such as cluster of differentiation 69 (CD69), as biomarkers of activity of TBX-3400	Preliminary efficacy assessment to measure activity of TBX-3400	8 months
Secondary	Presence and/or concentration of anti TBX-3400 antibodies	Measure of immunogenicity of TBX-3400	8 months